v The poor prognosis associated with central nervous system (eNS) malignancy has led investigators to seek new, innovative treatment modalities. Immunotoxins, carrier molecules linked to toxic agents, combine high specificity for tumor-associated antigens with extreme potency. The rationale for both the development of these compounds and for their application to eNS neoplasia is explained. This report discusses the design and construction of immunoconjugates, using toxins that differ in their mechanism of action bound to ligands directed against various antigens. A comparison is made between the in vitro efficacy of standard chemotherapy and immunotoxins in glioblastoma-and medulloblastoma-derived cell lines. A review is included of the results of experiments in animals with leptomeningeal neoplasia, where prolongation of survival following intrathecal administration of immunotoxins has been reported. The obstacles encountered in clinical trials with other types of cancer are addressed and approaches to optimize the use of these novel agents in the context of treating malignant disease of the eNS are suggested. A DVANCES in the conventional treatment of primary malignant tumors of the central nervous system (eNS), including surgery, radiation therapy, and systemic chemotherapy, have not improved the prognosis for this disease. 71.92.120.124,I38.139,l56 The 2-year survival rate for glioblastoma multiforme is still less than 20%.33,139 Retrospective studies have demonstrated that the increase in survival rate observed when surgical resection was the only treatment modality may not persist if additional postoperative treatment is rendered, particularly external beam irradiation.
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With the advent of monoclonal antibody technology, reagents have become available that selectively recognize cell-surface antigens expressed on neoplastic rather than normal tissues. 58 ,72.'36,'56.'57 Over the last 10 years, a large number of monoclonal antibodies that show high specificity for various types of tumor cells have been prepared.".52,58,85.91 Many of these antibodies have been chemically linked to drugs, radionuclides, and toxins in attempts to create more tumor selective therapeutic agents. 4.12,16,26 .69,76.77.90, 155 The biological heterogeneity of malignant gliomas and the variable expression of antigens among and within tumors have complicated the development of tumor-specific antibody-directed therapy.7.'7,'46.'56 Despite raising antibodies to human neuroectodermal tumor-and human glioma-associated antigens, polyclonal and monoclonal serological methodologies have not identified antigens specific for these tumor types. 14 . 33 Nevertheless, the presence of semispecific antigens on the surface of malignant brain-tumor cells may prove useful for designing new therapeutic modalities.'4.33.55,65,'56, '57 Immunotoxins, monoclonal antibodies, or other ligands directed against tumor-associated antigens covalently linked to toxic proteins constitute a new class of compounds designed to combine exquisite cell-type selectivity with extraordinary potency. 12.35,40,58,70,71.107,136, 156.157 The construction of immunotoxins is based on the "magic bullet" concept, linking toxic compounds to carrier molecules specific for a target cell, first introduced by Paul Ehrlich almost 100 years ago.27.58. 107, 156 Although only recently introduced to neurological surgery, immunotoxins have been in existence for 10 to 12 years. 35 .71. 156.157 In vitro studies using immunotoxins have shown cell-type specificity and high potency for various neoplastic tissue-culture cells, including those in glioblastomas multiforme and medulloblastomas. 24 .46,7I.!Ol,lI6.150,155.IS6 Unfortunately, in vivo immunotoxin study results have been much less satisfactory, possibly due to inadequate delivery or penetration into solid tumors by agents that often have molecular weights in excess of 175 kD.35.69.lso However, some early encouraging results have been provided by in vivo studies treating experimental CNS neoplasia with immunotoxins via compartmentalized administration, where transvascular delivery is not a factor. 157 The combination of excellent in vitro potency against many malignant cell types and the demonstration of in vivo efficacy when administered into a compartment has spawned an interest in using immunotoxins for the intrathecal treatment of clinical carcinomatous meningitis. 71
Rationale for Immunotoxin Therapy Many substances kill cells by destroying membrane integrity, disrupting energy metabolism, or blocking deoxyribonucleic acid, ribonucleic acid (RNA), or protein synthesis. Most standard chemotherapeutic drugs depend on the higher rate of replication of neoplastic cells as compared to normal cells to obtain a cytotoxic effect, and have limited potency for tumors with low growth factors.58.I3o.I34 The lack of specificity of systemic chemotherapy for malignant cells has led to doselimiting side effects and unacceptable toxicity.58 With immunotoxins, as with traditional chemotherapy, the establishment of a therapeutic window in which the dose produces antitumor activity without producing toxic side effects is necessary for clinical utility. Guided by their cell-type selective component toward neoplastic cells, immunotoxins have a mechanism of action affecting protein synthesis that is different and potentially superior to that of most chemotherapeutic agents. Moreover, hypoxia, a factor responsible for the resistance of tumor cells to radiation therapy and chemotherapy, has no effect on the mechanism of action of immunotoxins. 53 . 82 requires 20,000 alkylations to kill a single tumor cell and the alkylating agent 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) kills only 50% of human glioblastomaderived tissue-culture cells at concentrations as high as 10-3 to 10-6 M.23.74.119 In contrast, intact ricin immunotoxins can achieve the same result at a concentration of 10-13 M.156 Exact comparisons are difficult because of differences in assay technique; however, the extreme potency of immunotoxins by seven to 10 orders of magnitude over BCNU is apparent. The higher efficiency of immunotoxins is explained by their catalytic activity, reacting repeatedly with many intracellular targets once the toxin has reached the cytosol. These toxic enzymes inactivate over 200 ribosomes or elongation factor-2's per minute, irrespective of the cell cycle or cellular division, with only a single molecule necessary for cell death (Table 1) .28.58,100.148
Toxins Used to Produce Immunotoxins
The toxic moieties used to construct immunotoxins are natural by-products of bacteria, plants, or fungi, which in all cases enzymatically inactivate protein synthesis (Table 2) .58,107.136 Plant toxins used in producing immunotoxins for CNS tumor treatment include ricin and abrin or their A chains, pokeweed antiviral protein, modeccin, gelonin, saporin, and momordica charanthia inhibitor. Bacterial toxins include diphtheria toxin (DT), cross-reacting material (CRM) 107, and Pseudomonas aeruginosa exotoxin A. Alpha-sarcin is derived from a fungus. An extensive discussion of all toxins used in immunotoxin production is outside the scope of this article; emphasis will be placed only on those being developed for CNS use.
Most toxins, such as ricin, abrin, modeccin, and DT are composed of two polypeptide chains, an A chain and a B chain, linked by a disulfide bond. The 20-to 30-kD A chain, which causes cell death by inhibiting protein synthesis once inside the cytoplasm, is nontoxic to cells and animals. 101 The B chain binds toxins nonspecifically to cell-surface receptors on most eukaryotic cells and promotes internalization or translocation of the A 3T3 cells, whereas EGF bound to the DT A chain had no cytotoxic effects. When using a growth factor as the toxin carrier, there is a potential problem that the ligand may act to promote cellular growth if the amount of growth factor-toxin conjugate administered is less than the lethal dose. 35 Because of the high tissue specificity obtainable with monoclonal antibodies, most work has focused on their use as suitable binding ligands. The first immunotoxin constructed using a monoclonal antibody directed against a tumor-associated antigen was reported in 1980 by Gilliland, et al. 43 Approximately 50% colorectal carcinoma cells were killed after 24 hours when exposed to conjugates composed of the ricin or DT A chain and a monoclonal antibody to a colorectal carcinoma tumor-associated antigen at concentrations of 10-9 M.43 High tissue specificity and high antigen affinity are features that make some monoclonal antibodies useful for immunotoxin development. I I I Tumor-selective antibodies will bind 10 3 to 105 sites per cell in vitro and much less in vivo. ISO Antibodies that are effectively internalized make better immunotoxins than those that are not, as demonstrated in ovarian cancer cells. I I I Only a minority of monoclonal antibodies will yield an immunotoxin that is efficacious in animal models.
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Monoclonal antibody-directed toxin therapy should be targeted to cell-surface antigens or receptors that are produced in greater number on neoplastic cells than on normal cells. Although the function of most antigens is unknown, internalization of the antigen into an appropriate intracellular compartment with release of the toxin into the cytosol is necessary for cell killing, Unlike monoclonal antibody-linked high-energy radionuclides, which are cytotoxic when bound to the cell surface, toxins must enter the cell to cause an effect, and bystander cells are not influenced unless they express the same receptor or antigen on their surface.
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Potential cell membrane targets expressed on malignant tumors of the CNS in both cell culture and surgical samples are the EGF receptor (EGFR), a rearranged In Vitro Application
The observed in vitro cytotoxic activity of immunotoxins against malignant CNS disease offers promise that these agents may eventually reach clinical utility.
Zovickian, et aI., 156 reported that an antiTrR-ricin immunoconjugate, in the presence of the carboxylic ionophore monensin killed more than 50% of glioblastoma-and medulloblastoma-derived tissue-culture cells at a concentration of 5.6 x 10-13 M after 18 hours. The selective toxicity of the intact ricin-based immunotoxin against "target" cells compared to "nontarget" cells or normal brain tissue increased more than 150-to 1380-fold. Using an antiTrR-ricin A chain immunotoxin, Recht, et al.,"6 demonstrated a 50% inhibition of protein synthesis at concentrations ranging from 1.9 x 10-9 to 1.8 X 10-8 M in five human glioma cell lines. Co-incubation with monensin increased the toxicity of the immunotoxin against the glioma cells 16-to 842-fold. I 16 The mechanism by which monensin accelerates the action of the ricin A chain is unclear. 18.113
Johnson, et al.,71 reported a IO,OOO-foid increase in tumor-specific toxicity to glioblastoma-and medulloblastoma-derived cell lines using an immunotoxin made with CRM 107 as compared to free toxin. Cross-reacting material 107 coupled to human diferric Tr showed efficient killing of cell lines derived from medulloblastoma, glioblastoma multiforme, and breast carcinoma at concentrations between 3.9 x 10-13 and 1.1 x 10-10 M. Conjugates constructed using a monoclonal antibody to the human TrR 454AI2 and CRM 107 One report using intraperitoneal drug conjugates in nude mice bearing subcutaneous human glioma xenografts demonstrated that the SZ 39-ADR immunoconjugate had a greater antitumor effect than ADR alone or a nonspecific IgG-ADR conjugate. 
Clinical Trials
In clinical trials, immunotoxins have been used primarily to eliminate T-cells from allogeneic bonemarrow grafts to prevent graft-versus-host disease. syndrome and a severe sensorimotor peripheral neuropathy that developed in three patients 1 month after therapy, presumably due to cross-reactivity of the immunotoxin with Schwann cells. One partial response was seen, and antibody formation to the toxin and to the ligand was observed. Among 16 patients with metastatic colon cancer treated intravenously using an anti-72-kD glycoprotein-ricin A chain immunotoxin, Byers, et al., 15 noted two partial responses. Antibody production to both the murine immunoglobulin and to the ricin A chain was observed. 25 At the present time, the only reports of leptomeningeal tumor treatment using immunotoxins involve 131 1_ labeled monoclonal antibodies.
• 9o Moseley, et al.,90
treated 15 patients with neoplastic meningitis with between 11 and 60 mCi of antibody. The tumors treated included one pineoblastoma, one B-celllymphoma, one spinal teratoma, two melanomas, two glioblastomas muItiforme, four medulloblastomas, and one lung, one ovarian, one breast, and one bladder carcinoma. In patients with glioblastoma and medulloblastoma, 1311_ labeled antibodies were directed against a 230-kD glioma-associated glycoprotein and a primitive neuroectodermal-associated antigen, respectively. Seven of 15 patients experienced aseptic meningitis, manifesting as nausea, vomiting, and headache. Two patients had seizures and three of eight patients developed reversible bone-marrow suppression. Six patients sustained an objective response for 7 to 26 months. Three of four patients with medulloblastoma and both patients with gliomatosis had no response. 77 .
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A Phase I clinical trial using anti-TrR-recombinant ricin A chain immunotoxin therapy for patients with leptomeningeal neoplasia due to lung carcinoma, breast carcinoma, and lymphoma is presently being conducted at the National Institutes of Health.
Future Perspectives
Because of the poor prognosis for malignant disease of the CNS and current therapy offering little prolongation of survival, new, innovative treatment modalities are needed. Immunotoxins, which have demonstrated in vitro efficacy against primary and metastatic neoplastic disease of the CNS, may represent such a therapeutic option. Traditional therapy may be best for cytoreduction, reserving immunotoxins for the treat-ment of residual tumor cells. Combination chemotherapy is generally more effective than single-agent therapy; antibody-toxin conjugates might successfully be combined with other chemotherapeutic agents or radiation therapy because of a mechanism of action different from that of standard cancer treatments.38.39.I33. 141 The side effects of immunotoxin therapy, chemotherapy, and radiation therapy may therefore not be cumulative. 38 . 39 In a nude mouse model of colon cancer, it was recently shown that an immunotoxin administered with chemotherapy was more active than was either treatment alone. 136 An antiinterleukin 2 receptor-Po aeruginosa exotoxin A conjugate used to treat human T-cell leukemia caused significant liver toxicity, and neutralizing antibodies were seen within I week of systemic administration. 58 Other problems include cross-reactivity of the antibodies with normal cells and the heterogeneity of tumor cells, with regard to antigen expression, which can result in escape of genetic and phenotypic cell variants. 136 As demonstrated in clinical trials against malignant melanoma and breast carcinoma, the immune response mounted against the mouse monoclonal antibody and the toxin may present a difficult problem.37.123 A humoral immune response has been demonstrated to both the antibody and to the toxin in all cases except chronic lymphocytic leukemia. "immunologically privileged site" may offer protection from the host immune system. 145 The half-lives of native ricin A chain immunotoxins are as short as approximately 30 minutes, whereas deglycosylated or unglycosylated ricin A chain immunotoxins have half-lives of 4 to 6 hoursy·142 Mannosyl receptors on reticuloendothelial system cells and fructose receptors on hepatocytes may be responsible for the rapid clearance of these immunoconjugates from the blood. 13 Production of immunotoxins without oligosaccharides for future clinical trials is possible. The longer half-lives of deglycosylated forms may increase both their capillary penetration and their therapeutic efficacy.
A major potential difficulty of immunotoxin therapy stems from the large size of the molecules and the limited trans vascular diffusion into tumor tissue through an intact blood-brain barrier. 5 I Blood-brain barrier disruption with the osmotic agent mannitol has been used to treat primary CNS lymphoma with chemotherapeutic drugs and metastatic melanoma to the CNS with monoclonal antibodies. 93 ,95.96 As previously reported with BCNU, osmotic modification of the blood-brain barrier may be necessary with immunotoxins becau!>e of their size, particularly if the treatment of glioblastoma multi forme by the intra-arterial route is contempiated. 48 ,62 Although Gould, et al.,47 were unable to detect immunotoxin components bound to two breast carcinoma tumor biopsies obtained after treatment, the development of neurotoxicity and the presence of breast cancer epithelial antigen on nerve sheath tissue suggests that the conjugates were able to penetrate into the extravascular space. Conjugates have been made with IgG, Fab's, F(ab')/s, and recombinant forms; reducing the size of the antibody should increase tumor penetration and will hopefully reduce antigenicity.8.22.56,106 Using antibodies with a lower affinity for tumor cell-surface antigens may allow immunotoxins to percolate through the tumor interstitium and to attack more neoplastic cells. Recombinant technology has been used to develop immunotoxins effective in vitro and in viVO. 22 , 56, 106 Although there are few examples of the in vivo treatment of tumors involving the CNS, early results against leptomeningeal neoplasia are encouraging. Clinical trials directed against systemic cancer have demonstrated toxic side effects, such as peripheral neuropathy and capillary-leak syndrome, that may be avoided by an intact blood-brain barrier and the compartmentalized nature of the eNS. Since recombinant human alpha-interferon has been shown to potentiate the action of immunotoxins both in vitro and in vivo against a human ovarian carcinoma cell line, co-instillation of alpha-interferon and immunotoxins into the intrathecal space of patients with carcinomatous meningitis may prove clinically efficacious. 109 In addition, alpha-interferon could be administered with immunotoxins by an intratumoral approach into glioblastomas multiforme, as has been reported previously with interleukin-2 and and the calcium channel-blocking agents verapamil and diltiazem, I may be used in combination with immunotoxins if intrathecal or intratumoral delivery is considered.
Conclusions
In this review, we have described the development of immunotoxin therapy as it pertains to the treatment of CNS neoplasia. At the present time, most work has focused on the construction of individual conjugates that are effective in vitro against malignant CNS disease. Future in vitro efforts should include the determination of the most optimal combinations of ligand and toxin and efforts to increase the efficiency of toxin translocation into neoplastic cells, Considerations for improving the clinical effect of immunotoxins might include rendering the patient tolerant or unresponsive to the antibody-toxin conjugate by reducing the immune response via drug administration, by performing total nodal irradiation, or by inducing tolerance to murine and toxin proteins. The establishment of animal models of human neoplastic meningitis 41 with various tumor types known to spread to the CNS and via cerebrospinal fluid pathways is necessary to further 
